PSA-detected (clinical stage T1c or B0) prostate cancer: Pathologically significant tumors

J. E. Oesterling, V. J. Suman, H. Zincke, D. G. Bostwick

Research output: Contribution to journalArticlepeer-review

95 Scopus citations


With the rapidly spreading enthusiasm for early detection of prostate cancer and the increasing use of serum PSA to evaluate the gland, more cancers that are not palpable on digital rectal examination are being identified. These tumors have pathologic characteristics that are very similar to those of clinically localized, palpable prostate cancers identified on digital rectal examination. Thus, the tumors detected on the basis of an elevated serum PSA value should not be disregarded as insignificant. In fact, these tumors should be given the same therapeutic consideration as the clinically localized, palpable cancers. In the TNM staging system, 'PSA-detected' cancers can be classified as stage T1c, and in the Whitmore-Jewett staging system, they can be referred to as stage B0. Long term follow-up of these prostate cancers will be necessary to establish the prognosis.

Original languageEnglish (US)
Pages (from-to)687-693
Number of pages7
JournalUrologic Clinics of North America
Issue number4
StatePublished - Dec 1 1993

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'PSA-detected (clinical stage T1c or B0) prostate cancer: Pathologically significant tumors'. Together they form a unique fingerprint.

Cite this